Biolegend, 423109, Zombie Red™ Fixable Viability Kit
100tests
Catalog Number: 423109
Send an RFQ.
Category
Pack Size1 vial
Loading…
| Preparation | Zombie Red™ Fixable Viability kit is composed of lyophilized Zombie Red™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Red™ dye until fully dissolved. 100 tests = 1 vial of Zombie Red™ + DMSO, 500 tests = 5 vials of Zombie Red™ + DMSO. |
|---|---|
| Storage & Handling | Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Red™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month. |
| Application | FC - Quality tested ICFC, ICC - Verified |
| Recommended Usage | Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunocytochemistry, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type. |
| Excitation Laser | Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| Zombie Red™ dye is excited by the yellow/green laser (561 nm) and has fluorescence emission maximum at 624 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Red™ dye has similar emission to PE-Texas Red. Zombie Red™ can be weakly excited by the 488 laser, if a yellow/green laser is not available. This may require a higher concentration of Zombie Red™ dye; optimization by the end user would be required. Standard Cell Staining Protocol: Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Red™ dye and mix until fully dissolved Wash cells with PBS buffer (no Tris buffer and protein free). Dilute Zombie Red™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Red™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA. Continue performing antibody staining procedure as desired. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation. No-wash Sequential Staining Protocol: Wash cells with PBS buffer (no Tris buffer and protein free). For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Red™ dye and mix until fully dissolved Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie Red™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie Red™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Red™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells. Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Red™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Red™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Red™. |
| Product Citations | Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed Yeh WW, et al. 2022. J Virol. 96:e0075522. PubMed Zlei M, et al. 2022. Cells. 11:. PubMed Sugrue JA, et al. 2022. Cell Rep Med. 3:100804. PubMed Pothast CR, et al. 2022. Elife. 11:. PubMed Evans JG, et al. 2023. Viruses. 15:. PubMed Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed Aleksova M, et al. 2023. Diagnostics (Basel). 13:. PubMed Chen Z, et al. 2023. Nat Commun. 14:3469. PubMed Fantone K, et al. 2021. Pathogens. 10:. PubMed Mu L, et al. 2023. Front Immunol. 13:842524. PubMed Roberts JL, et al. 2022. Bone. 157:116310. PubMed Krausgruber T, et al. 2020. Nature. 583:296. PubMed Geuijen C, et al. 2021. Nat Commun. 12:4445. PubMed Robertson N, et al. 2022. Nat Commun. 13:649. PubMed Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed Ligorio M, et al. 2019. Cell. 178:160. PubMed Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed Rota CM, et al. 2022. Neurooncol Adv. 4:vdac049. PubMed Yen WF et al. 2019. Cell reports. 27(5):1472-1486 . PubMed Wurzer H, et al. 2021. Front Immunol. 12:619069. PubMed Ummarino S, et al. 2021. Cells. 10:. PubMed Sperber HS, et al. 2019. Sci Rep. 9:707. PubMed Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed Trompette A, et al. 2022. Mucosal Immunol. :. PubMed Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed Mousseau G, et al. 2019. MBio. 10. PubMed Huang Y, et al. 2022. iScience. 25:105209. PubMed Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed Lim J, et al. 2022. J Exp Med. 219:. PubMed Gopinath A, et al. 2022. NPJ Parkinsons Dis. 8:72. PubMed Martin C, et al. 2017. PLoS One. 10.1371/journal.pone.0170504. PubMed Mercer F, et al. 2016. PLoS Negl Trop Dis. 10: 0004913. PubMed Brennan FH, et al. 2019. JCI Insight. 4. PubMed Georg P, et al. 2022. Cell. 185:493. PubMed Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed Juette MF, et al. 2022. Elife. 11:. PubMed O'Meara CP, et al. 2021. Commun Biol. 4:1201. PubMed Virtakoivu R, et al. 2021. Clin Cancer Res. 27:4205. PubMed Yewdell WT, et al. 2021. Cell Rep. 37:109961. PubMed Ubags ND, et al. 2021. J Allergy Clin Immunol. 1049:147. PubMed Jolly A, et al. 2022. Cell Rep Methods. 2:100315. PubMed Swarnalekha N, et al. 2021. Sci Immunol. 6:. PubMed Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed Sandlin CW, et al. 2022. PLoS One. 17:e0274091. PubMed Riopel M, et al. 2019. Mol Metab. 20:89. PubMed |
|---|
| Biology Area | Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience |
|---|
| Gene ID | NA |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Fixable Dye, Fixable Viability Dye, Dead, Apoptosis |
|---|
